EBITDA

Lindsay Corp.'s massive irrigation project in MENA isn't just a sale; it's a strategic move in the high-stakes race to solve global food security.

The EU's landmark decision to ease rules on New Genomic Techniques opens a multi-billion dollar market, and ag-tech pioneer Cibus is ready to cash in.

Sarepta Therapeutics is trading higher interest costs for a longer financial runway. We decode the biotech's complex debt deal and what it signals.

The U.S. Coast Guard taps AeroVironment for advanced underwater robots, a key step in its Force Design 2028 plan to boost safety and mission efficiency.

As agencies retool for a complex market, Bastion's appointment of a cultural PR expert highlights a critical shift for pharma and beyond.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

As EVgo nears breakeven, it brings in a seasoned financial architect from the energy sector to steer its capital-intensive buildout toward profitability.

Fidelity and TIAA still lead, but strategic AI investments are fueling a surge from mid-tier players, redefining the competitive retirement landscape.

Beyond the hype, one company's dual leadership award reveals the true engine of the GenAI revolution: a smarter, more powerful search foundation.

A single crypto campaign generates $53.5B in futures volume. We dissect MEXC's strategy and what it reveals about the exchange wars and token adoption.

Biotech startup Bio Usawa appoints a world-renowned health expert to lead its access board, betting its entire business model on making advanced drugs affordable.

CEAT Specialty's new OTR tyre isn't just rubber—it's a strategic play for India's trillion-dollar infrastructure push, blending tech and market savvy.

Bill Ackman's fund posted a stellar 24.1% return. We dive into the high-conviction plays and innovative structure driving this market-beating performance.

OMRON's new global ECG strategy leverages AI and key acquisitions to tackle heart disease, aiming to eliminate adverse cardiovascular events.

A new contract for TGS in Brazil signals enduring appeal for offshore oil. Discover how 4D seismic is unlocking value in mature, complex energy fields.

With a massive $550M capital infusion, Immunovant is poised to accelerate its novel Graves' Disease therapy, IMVT-1402, toward commercial launch.

A Belgian med-tech firm is replacing a centuries-old procedure with an implantable pump, targeting a growing multi-billion dollar liver disease market.

A new solar-plus-storage project in Sicily showcases how tailored energy solutions can boost industrial autonomy, cut costs, and withstand harsh climates.

The industrial giant secured a rare dual 'A' rating from CDP. We decode what this means for its strategy, competitors, and ESG-focused investors.

A new 8MWh energy storage system in Matsusaka showcases how advanced technology is helping Japan balance industrial power with its green energy ambitions.